Tabirafusp Tedromer for Diabetic Macular Edema

(ALTO Trial)

This trial tests a new treatment called Tabirafusp Tedromer for individuals with diabetic macular edema (DME), an eye condition that can impair vision in those with diabetes. Researchers aim to determine if this new treatment is more effective and safe compared to the existing treatment, Aflibercept. Participants will receive injections of either Tabirafusp Tedromer or Aflibercept in their eyes to manage their condition. Individuals with diabetes and DME who have not received eye treatments before or have tried other treatments may be suitable for this study. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment for DME.

Research has shown that Tabirafusp Tedromer demonstrated promising safety results in earlier studies. Most participants handled the treatment well, with side effects typically mild to moderate. Serious side effects occurred rarely, and the treatment's safety aligned with expectations for similar drugs.

Aflibercept, already approved by the FDA for other uses, has a strong safety record. Past research indicates that most patients tolerate it well, with common side effects being manageable.

Researchers are excited about Tabirafusp Tedromer for diabetic macular edema because it offers a fresh approach compared to standard treatments like aflibercept. Unlike traditional therapies, Tabirafusp Tedromer is a fusion protein that may enhance the body's immune response specifically in the eye, potentially leading to better control of inflammation and fluid leakage. The flexibility in its dosing schedule, which can be tailored from every four weeks up to every 24 weeks, also presents a significant advantage, offering the potential for fewer injections and a more convenient treatment option for patients.

Research has shown that aflibercept, one of the treatments in this trial, effectively treats diabetic macular edema. Patients using aflibercept have experienced significant vision improvements because it reduces fluid buildup in the retina by blocking proteins that cause blood vessels in the eye to leak.